^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | varlitinib (ASLAN001) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumors, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer
Excerpt:
...Tumor is HER2 positive either by IHC (3+) or FISH amplification (amplification ratio >2.0)...
Trial ID:
Source:
Title:
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
Published date:
02/23/2022
Excerpt:
The majority of patients with a PR had HER2+ metastatic breast cancer….Patients with HER2+ metastatic breast cancer (*) [HER2+ MBC] tended to have longer PFS (median PFS 5.4 months, range 1.2–17.1 months)….The median duration of maintenance single-agent varlitinib therapy was 5.1 months (range 2.0–13.3 months) without disease progression in these patients. All eight patients had HER2+ metastatic breast cancer.
DOI:
10.1007/s11523-022-00867-0
Trial ID:
Source:
Title:
Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
Published date:
05/16/2018
Excerpt:
20/37 had HER2+ metastatic breast cancer (MBC) with median 4 (0-14) prior treatment lines. 7 achieved partial response (PR) and 3 stable disease (SD)...The RD of V combined with P is 300mg BD int, and is active in HER2+ MBC…
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2018.36.15_suppl.2588
Trial ID:
